Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Research Themes

Metabolism (Collaborator)

Clinical Trials

IMAGO: A single arm exploratory study examining the feasibility of imaging glioblastoma pH using CEST MRI

NEOPANC-01: A phase 0, pre-operative, window-of-opportunity study to assess gene expression in patients with resectable pancreatic cancer 

WINGMEN: Windows trial of INsulin-like Growth factor neutralising antibody Xentuzumab in MEN scheduled for radical prostatectomy

A Cancer Research UK Phase I/IIa open label, dose escalation and expansion trial of HMBD-001 (an anti-HER3 monoclonal antibody) given intravenously as a single agent and in combination in patients with advanced HER3 positive solid tumours

A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies

A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers

Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors - CONTRAST

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination with Anti-PD-L 1 (Atezolizumab) in Adult Patients with Selected Advanced Malignancies

A Translational Phase 1/2 Dose-Escalation and Expansion Study to Determine Safety, Tolerability, and Recommended Phase 2 Dose of RSO-021 in Patients with Malignant Pleural Effusion due to Advanced/Metastatic Solid Tumors including Mesothelioma

A phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (PETRA)

Simon Lord

Associate Professor in Experimental Cancer Therapeutics

  • Director, Early Phase Clinical Trials Unit, Department of Oncology, University of Oxford
  • Consultant Medical Oncologist, Oxford University Hospitals NHS Foundation Trust
  • Senior Research Fellow, Oriel College
  • OUCAGS Foundation Programme Academic Lead


My research interests focus on the development of new drugs to treat breast cancer. I also lead a number of clinical studies assessing how novel metabolic imaging signatures may reflect tumour biology.


Simon Lord has been director of the Early Phase Clinical Trials Unit in the Department of Oncology since 2021. He undertook his medical oncology training in Leeds before moving to Oxford to pursue his DPhil and take up a Cancer Research UK Clinical Research Fellowship. He was appointed Senior Clinical Researcher in Experimental Cancer Therapeutics in the Department of Oncology in 2015 and is a consultant medical oncologist at the Oxford Cancer Centre. He is the Against Breast Cancer Senior Research Fellow at Oriel College and is a module lead for the Precision Cancer Medicine MSc at the University of Oxford. Since 2021 he has also been a Foundation Programme Academic Lead for the Oxford University Clinical Academic  Graduate School (OUCAGS). He is chief and principal investigator for several clinical trials including first in human drug and novel imaging studies.